Peptidylprolyl Isomerase a Regulates DNA Damage Repair and Serves as a Prognostic Biomarker in Lung Adenocarcinoma Authors: Li Zou, Bixin Ren, Ying Wan, Xin Wang, Ruichi Shen, Wenlang Zhu, Limin Jin, Qiliang Peng, Ye Tian Published: 2026 ABSTRACT AbstractBackgroundThis study investigated the role of peptidylprolyl isomerase A (PPIA) in lung adenocarcinoma (LUAD) using bioinformatics approaches and experimental validation.MethodsThis study began by assessing PPIA expression and its prognostic significance in LUAD. We then performed functional enrichment analyses and examined CNVs, DNA methylation, DNMT activity, RNA modification, immune cell infiltration, and drug therapy efficacy. Cellular experiments were performed to confirm the role of PPIA in DNA damage repair.ResultsPPIA was overexpressed in LUAD tissues and was associated with poor prognosis, including shorter overall survival and progression-free interval. PPIA expression was correlated with CNVs, DNA methylation, DNMT activity, and RNA modification-related genes. It was also negatively associated with immune cell infiltration and immune-related gene expression, suggesting a potential immunosuppressive role. Drug sensitivity analysis indicated that PPIA may serve as a predictive biomarker for therapeutic efficacy in LUAD. In addition, PPIA expression was associated with DNA damage repair-related genes. Cellular experiments show that PPIA knockdown increases radiosensitivity and γ-H2AX foci formation, whereas PPIA overexpression exerts the opposite effects.ConclusionThis study highlights the potential of PPIA as a prognostic biomarker and target in LUAD, particularly in the regulation of DNA damage repair and tumor immune microenvironment remodeling.Keywords: lung adenocarcinoma, PPIA, prognosis, biomarker, DNA damage repair Introduction Lung cancer remains one of the most commonly diagnosed malignancies and the leading cause of cancer-related mortality worldwide. 1 Lung adenocarcinoma (LUAD), the predominant subtype of non-small cell lung cancer (NSCLC), represents a major clinical challenge despite recent advances in targeted therapy and immunotherapy. 2 Although these treatments have improved outcomes for selected patients, many individuals with LUAD still experience disease progression, therapeutic resistance, and an immunosuppressive tumor microenvironment. 3 Therefore, identifying novel biomarkers and therapeutic targets is essential for improving prognostic stratification and treatment strategies in LUAD. 4 Peptidylprolyl isomerase A (PPIA), also known as cyclophilin A (CypA), encodes a member of the peptidyl-prolyl cis-trans isomerase (PPIase) family. PPIases catalyze the cis-trans isomerization of prolyl peptide bonds and participate in protein folding, trafficking, and functional regulation. PPIA also binds cyclosporin A and is involved in cyclosporin A-mediated immunosuppression. 5 PPIA has emerged as a pivotal player in the onset and progression of various diseases, including inflammatory diseases, COVID-19 infections, and cancer. 6 Increased expression of PPIA is associated with enhanced cancer cell proliferation, invasion, therapeutic resistance, and the acquisition of stem cell-like properties, all of which are linked to poorer outcomes for cancer patients. 7 A study by Liu et al. demonstrated that PPIA expression inversely correlates with patient prognosis and is negatively associated with immune cell infiltration and immune cell markers in gastric cancer. 8 In this study, we analyzed PPIA expression in LUAD, its clinical significance, diagnostic/prognostic value, co-expression, functional enrichment, DNA methylation, and immune correlations (scores, infiltration, markers). Bioinformatics and biological experiments validated our findings. The research methodology is outlined in the flowchart presented in Figure 1. Flowchart of this study Materials and Methods Data Sources and Sample Sizes The transcriptomic and clinical data used in this study were obtained from publicly available databases. For TCGA-LUAD analysis, RNA-seq data from 527 LUAD tumor samples and 49 adjacent normal lung samples were included. Three GEO datasets were used for external validation: GSE31210 (n = 246), GSE10072 (n = 107), and GSE40791 (n = 194). Samples with missing expression values or incomplete clinical information were excluded from analyses requiring the corresponding variables. Expression Analysis of PPIA PPIA expression in normal tissues was explored via the Genotype-Tissue Expression (GTEx) database, and its expression across cancers was investigated using TCGA data, with a focus on LUAD tissues versus normal and adjacent non-cancerous tissues. GEO datasets (GSE31210, GSE10072, GSE40791) validated PPIA expression in LUAD. The Kruskal-Wallis test examined correlations between PPIA expression and clinicopathological parameters (T, N, M stages). PPIA protein expression was analyzed by immunohistochemistry using the Human Protein Atlas (HPA) database to compare normal and LUAD tissues. Diagnosis and Survival Analysis of PPIA PPIA’s diagnostic value in LUAD was assessed by receiver operating characteristic (ROC) analysis using the “pROC” package. The “survival” package elucidated correlations between PPIA expression and cancer patients’ overall survival (OS) and progression-free interval (PFI), visualized via forest plots, heat maps, and Kaplan-Meier curves. For Kaplan-Meier survival analysis, patients were divided into high- and low-PPIA expression groups according to the median PPIA expression value within each cohort. The “forestplot” package performed univariate and multivariate analyses to identify independent factors. A prognostic nomogram was constructed using the “rms” package based on multivariate Cox regression, and a calibration curve verified its reliability in predicting 1-, 3-, and 5-year OS. Network and Functional Enrichment Analysis of PPIA The STRING database identified the top 50 PPIA-interacting proteins and constructed a protein-protein interaction (PPI) network. 9 Functional enrichment analyses (Gene Ontology [GO] and Kyoto Encyclopedia of Genes and Genomes [KEGG] pathways) of these proteins were conducted using the “clusterProfiler” package in R. Co-Expression Genes Analysis of PPIA The LinkedOmics database (featuring LinkFinder, LinkInterpreter, LinkCompare modules) 10 analyzed PPIA co-expressed genes. The top 100 PPIA-associated genes (positive/negative) were visualized via volcano plots and heatmaps. Survival maps explored correlations between the top 50 associated genes and LUAD patients’ OS and disease-free survival (DFS). GSEA Analysis of PPIA Differential PPIA expression was analyzed using “DESeq2” and “edgeR” packages based on TCGA-LUAD data. For GSEA, LUAD samples were divided into high- and low-PPIA expression groups using the median PPIA expression value as the cutoff. Genes were ranked according to differential expression between the high- and low-PPIA groups. A co-expression heatmap presented correlations of the top 10 up/down-regulated genes in high-PPIA groups. Gene Set Enrichment Analysis (GSEA) was performed via “clusterProfiler” to identify related hallmarks, with statistically significant results visualized as mountain plots using the “ggplot2” package. Correlation Analysis Between PPIA and DNA Damage Repair-Related Genes To further explore the potential mechanistic link between PPIA and DNA damage repair, we analyzed the correlation between PPIA expression and representative DNA damage repair-related genes in the TCGA-LUAD cohort. Genes involved in DNA damage checkpoint signaling, homologous recombination, non-homologous end joining, base excision repair, nucleotide excision repair, and mismatch repair were included. Spearman correlation analysis was performed to evaluate the associations between PPIA and these genes. The results were visualized using a correlation heatmap, and p < 0.05 was considered statistically significant. Correlation Between PPIA Expression and CNVs, DNA Methylation and Methyltransferases The GSCA web platform examined copy number variations (CNVs) and PPIA expression across malignancies. The MethSurv tool 11 analyzed PPIA DNA methylation levels and the predictive value of each CpG site. The association between PPIA expression and three DNA methyltransferases (DNMTs) was graphically analyzed. Heatmaps visualized PPIA’s relationship with genes involved in m6A, m5C, and m1A modifications. Correlation Analysis of PPIA and Immune Cell Infiltration The TIMER database, 12 integrating transcriptional and clinical data, was used to present correlations between PPIA expression and immune infiltrating cells across cancers via heatmaps. Single-Cell Analysis of PPIA The Tumor Immune Single-cell Hub 2 (TISCH2), 13 a scRNA-seq repository focused on the tumor microenvironment (TME), was employed for detailed single-cell analysis of PPIA expression in LUAD immune-infiltrating cells. Correlation Analysis of PPIA and Tumor Microenvironment The “estimate” R package explored correlations between PPIA expression and immune microenvironment scores (stromal, immune, estimate scores), which reflect interactions among immune cells, tumor cells, and non-immune cells in the TME. Correlation Analysis of PPIA and Immune Related Genes TCGA data explored PPIA’s relationship with immune checkpoint genes and deficient mismatch repair (dMMR)-linked genes, visualized via heatmaps. Spearman correlation analysis examined PPIA’s associations with immune modulators (MHC genes, chemokines, chemokine receptors), with results shown in heatmaps and radar charts. Predictive Role of PPIA in Drug Therapy Efficacy The GSCA database (https://bioinfo.life.hust.edu.cn/web/GSCALite/) assessed PPIA expression and drug sensitivity, complemented by GDSC and CTRP pharmacological data. The BEST database (https://rookieutopia.com/) performed immunotherapy response analysis. PPIA expression was compared between response (R) and non-response (NR) groups using Wilcoxon rank-sum (non-normal) or independent samples t-test (normal) (p < 0.05). Boxplots visualized differences; ROC curves evaluated immunotherapy prediction efficacy. Kaplan-Meier curves compared OS/PFS between high/low-PPIA groups (log-rank test, p < 0.05), with “number at risk” labeled at key time points. Cell Culture Lung cancer cell lines A549 and H1299, sourced from ATCC, were cultured in DMEM supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. Cells were incubated in a humidified 5% CO2 atmosphere at 37 °C. Mycoplasma contamination was ruled out using the MycoAlertTM Mycoplasma Detection Kit. Antibodies and Reagents The following antibodies and reagents were used: anti-PPIA (10720-1-AP, Proteintech), anti-γ-H2AX (ab81299, Abcam), CCK-8 (C0039, Beyotime). Plasmids, shRNA, and Transfection PPIA-targeting lentiviral shRNA (shRNA#1: GGT​GTT​TGG​CAA​AGT​GAA​AGA; shRNA#2: GGT​GGC​TCA​CTG​TCT​GTA​ATG), overexpression plasmids, and control shRNA were from Genechem. Transfection was performed with Lipo3000 (Invitrogen) per manufacturer’s protocol. Western Blot Cells were lysed with RIPA Lysis Buffer. Lysates underwent SDS-PAGE, transferred to PVDF membranes, and incubated with primary antibodies at 4 °C, followed by secondary antibodies at room temperature. Signals were detected with Super ECL Plus Kit, normalized to β-actin. Cell Irradiation A549 and H1299 cells were irradiated with 4 Gy using an X-RAD 320iX biological irradiator (Precision X-ray, North Branford, CT, USA) at a dose rate of 1.1 Gy/min to conduct a radiosensitivity study. The 4 Gy dose was selected based on previous studies using A549 and H1299 lung cancer cells, in which this dose induced measurable radiation-related cellular responses while allowing subsequent assessment of radiosensitivity and DNA damage repair. 14 This dose was therefore considered suitable for evaluating γ-H2AX foci formation and the role of PPIA in radiation-induced DNA damage repair. CCK-8 Cells were plated in 96-well plates, incubated with DMEM + 10 μl CCK-8 at 37 °C for 2 h. Absorbance was measured at 450 nm via microplate reader. Immunofluorescent (IF) Staining Tumor cells were seeded in confocal plates, fixed with 4% polyformaldehyde, permeabilized with 0.1% Triton X-100, blocked with goat serum, and incubated with anti-γ-H2AX primary antibody at 4 °C overnight. After PBS washes, cells were incubated with Alexa FlourTM 594 secondary antibody and DAPI mounting medium. Images were captured via confocal microscope and analyzed with LAS X software. Statistical Analysis All bioinformatics and statistical analyses were performed using R software version 4.4.3 and GraphPad Prism 7.0 unless otherwise specified. Data from cellular experiments are presented as mean ± standard deviation (SD) from three independent biological replicates. Unpaired Student’s t-test or one-way ANOVA was used to compare groups. Kaplan-Meier method was used to analyze survival curves. p < 0.05 indicated statistical significance. Results The Expression Patterns of PPIA GTEx analysis showed baseline PPIA expression across 29 normal tissues (Figure 2A). Both TCGA and TCGA-GTEx data revealed significant PPIA upregulation in nearly all tumors versus normal tissues (Figure 2B-C). In LUAD, PPIA was highly expressed compared to normal/adjacent tissues (Figure 2D-E), validated by three GEO datasets (p < 0.001, Figure 2F-H) and significantly correlated with clinicopathological stages (T, N, M, pathological stage, Figure 2I-L). IHC confirmed higher PPIA protein in LUAD (Figure 2M). ROC curves indicated good diagnostic efficacy, with AUCs of 0.776 (TCGA, Figure 2N) and 0.839 (TCGA-GTEx, Figure 2O). Analyses of PPIA expression. (A) The expression of PPIA in normal tissues based on GTEx database; (B) The expression levels of PPIA in tumor tissues and adjacent normal tissues based on TCGA; (C) The expression levels of PPIA in tumor tissues and adjacent normal tissues by combining TCGA and GTEx. (D-E) PPIA expression in LUAD compared to both normal tissue (D) and matched adjacent normal tissues (E). (F-H) The expression level of PPIA in the GSE31210 (F), GSE10072 (G), and GSE40791 (H) datasets, contrasted with the respective control samples. (I-L) Association between the PPIA expression and different clinicopathological characteristics in LUAD including T stage (I), N stage (J), M stage (K), and clinical stage (L). (M) Representative images of PPIA protein expression of LUAD tissues. (N-O) ROC analysis of PPIA in LUAD based on TCGA (N) and TCGA+GTEx (O). * p < 0.05; ** p < 0.01; *** p < 0.001 PPIA is Associated With Survival Outcomes in Different Cancer Types Pan-cancer analyses revealed that high PPIA expression predicted poor OS and PFI across multiple cancers (Figure 3A-D), as supported by Kaplan-Meier curves for representative types (Figure 3E-P). Prognostic relevance of PPIA in pan-cancer. (A-D) Forest plots and heat maps were used for pan-cancer analyses of PPIA and OS (A, B), PFI (C, D). (E-J) Kaplan-Meier survival curves to depict the impact of PPIA on OS for ACC (E), HNSC (F), LIHC (G), LUAD (H), PAAD (I), UVM (J). (K-P) the impact of PPIA on PFI for ACC (K), HNSC (L), LIHC (M), LUAD (N), PAAD (O), UVM (P). * p < 0.05; ** p < 0.01; *** p < 0.001 In LUAD, univariate analysis identified T, N, M stages, and PPIA as prognostic factors for OS (Figure 4A). Multivariate analysis confirmed PPIA, T stage, and N stage as independent risk factors (Figure 4B). A nomogram combining these three variables was established to predict 1-, 3-, and 5-year OS (higher scores indicating worse prognosis, Figure 4C), and calibration plots showed good agreement between predicted and actual outcomes (Figure 4D). Prognostic value of PPIA in LUAD. (A-B) The forest plot of univariate (A) and multivariate (B) regression analysis result of PPIA in LUAD. (C) A nomogram to estimate the 1, 3, and 5-year survival rates of patients with LUAD. (D) The calibration plots to evaluate the agreement between the estimated and actual OS PPIA is Implicated in the Regulation of Signaling Pathways PPIA is implicated in regulating signaling pathways. A STRING-based PPI network was built for 50 PPIA-interacting proteins (Figure 5A). KEGG analysis showed enrichment in immune and signaling pathways such as T/B cell receptor signaling, PD-L1/PD-1 checkpoint, NK cell cytotoxicity, Th1/Th2 differentiation, MAPK, and VEGF signaling (Figure 5B). GO analysis demonstrated that these proteins regulate DNA metabolism, protein dephosphorylation, and cell cycle/DNA damage checkpoints (BP, Figure 5C); localize to DNA repair/phosphatase complexes, chromosomal regions, and replication forks (CC, Figure 5D); and function in phosphatase and phosphoprotein binding activities (MF, Figure 5E). Functional enrichment analysis and the co-expression genes of PPIA. (A) A PPI network for PPIA-interacting genes. (B) KEGG pathway analysis of PPIA-interacting genes. (C-E) GO analysis of PPIA-interacting genes: Biological process (C), Cellular component (D), Molecular function (E). (F) The whole significantly related genes with PPIA identified by Pearson test by LinkedOmics database in LUAD. (G) Heatmap of the top 50 genes positively related to PPIA in LUAD. (H) Heatmap of the top 50 genes negatively related to PPIA in LUAD. (I-J) Survival maps depicting the correlation between the top 50 genes most positively correlated with PPIA and OS (I), DFS (J) in LUAD. (K-L) Survival maps depicting the correlation between the top 50 genes most negatively correlated with PPIA and OS (K), DFS (L) in LUAD PPIA has a Synergistic Effect With its Co-expressed Genes The LinkedOmics database identified genes significantly associated with PPIA, with heatmaps displaying the top 50 positively and negatively correlated genes. Survival plots showed nearly all PPIA-positively correlated genes had detrimental HRs for LUAD OS and DFS, while negatively correlated genes mostly had favorable HRs (Figure 5F-L). These findings suggest co-expressed genes are potential LUAD biomarkers and may synergize with PPIA in LUAD prognosis. PPIA is Featured by Specific Hallmarks The heat map depicted the top ten genes that exhibited both positive and negative correlations with the PPIA gene (Figure 6A). During the GSEA examination of PPIA, a landscape plot was employed to depict the hallmarks potentially linked to the initiation and advancement of cancerous growths (Figure 6B). Hallmarks related to cancer included: E2F targets, MYC targets V1, G2/M checkpoint, mTORC1 signaling, MYC targets V2, interferon alpha response, interferon gamma response, epithelial mesenchymal transition, KRAS signaling DN, and p53 pathway (Figure 6C-L). Gene set enrichment analysis of PPIA in LUAD. (A) The top ten genes that up-regulated or down-regulated in LUAD with high PPIA expression. (B) Hallmark GSEA enrichment plots. (C-L) Representative hallmark plots PPIA Expression is Associated With Increased Genomic Alteration Frequencies Supplementary Figure S1 presents the genomic alteration landscape of PPIA in LUAD, providing foundational insights into the genetic variations of this gene in the disease context. We stratified patients by PPIA expression levels and visualized the mutation profiles of the top 20 most frequently mutated genes in the cohort. This analysis revealed that the high PPIA expression group harbored significantly more mutations such as TP53 and CSMD3 within this gene set. In addition, we found that the gain of chromosome segment 7p11.2 was more frequent in the high PPIA expression group while the loss of some chromosome segments such as 5q12.1 were more frequent in the high PPIA expression group. PPIA is Highly Correlated With CNVs, DNA Methylation and Methyltransferases PPIA expression positively correlated with CNVs in specific cancer types (Figure 7A and B). MethSurv analysis revealed the prognostic value of PPIA DNA methylation, with methylation levels at cg26194633 and cg25980157 significantly correlating with patient survival (Figure 7C-E). Additionally, PPIA expression positively correlated with the activity of DNMT1, DNMT3A, and DNMT3B across various cancers, which was especially pronounced in LUAD (Figure 7F). Furthermore, PPIA expression showed a marked positive correlation with RNA modification genes in certain cancers. In LUAD, this correlation was particularly evident across m6A-, m5C-, and m1A-related genes (Figure 8A-C). PPIA is associated with CNVs, DNA methylation and methyltransferases. (A-B) Relationship between CNVs and the expression levels of PPIA across different cancers: heatmap (A) and radar chart (B). (C) DNA methylation status within the PPIA gene was significantly correlated with the clinical outcome of LUAD patients. (D-E) cg26194633 and cg25980157 exhibited a significant correlation between methylation levels and patients’ survival. (F) Correlations between PPIA and three DNMTS. * p < 0.05; ** p < 0.01; *** p < 0.001 Correlations between PPIA levels and RNA modulations. (A) m6A-related genes. (B) m5C-related genes. (C) m1A-related genes. * p < 0.05; ** p < 0.01; *** p < 0.001 PPIA is Significantly Correlated With the Infiltration of Immune Cells PPIA expression was negatively correlated with infiltration of B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and dendritic cells in multiple cancers (Figure 9A). Seven algorithms (CIBERSORT, CIBERSORT-ABS, XCELL, EPIC, MCPCOUNTER, QUANTISEQ, TIMER) confirmed this inverse correlation, especially in LUAD (Figures 9B-D). Single-cell analysis showed PPIA was highly expressed in various immune cells across datasets (GSE131907, GSE143423), suggesting a key role in immune cells (Figure 10). Correlation of PPIA expression with the infiltration of immune cells. (A) The relationship between PPIA expression and the infiltration of various immune cells. (B) Correlation of PPIA expression with the infiltration of B cells by different algorithms. (C) Correlation of PPIA expression with the infiltration of CD8+ T cells by different algorithms. (D) Correlation of PPIA expression with the infiltration of CD4+ T cells by different algorithms. * p < 0.05; ** p < 0.01; *** p < 0.001 The expression level of PPIA in a variety of immune cells. (A) The expression level of PPIA in a variety of immune cells in different datasets. (B-D) The expression of PPIA across various immune cell types within the GSE131907 dataset. (E-G) The expression of PPIA across various immune cell types within the GSE143423 dataset PPIA is Highly Involved in the Tumor Immune Microenvironment A heatmap presented in Figure 11A visualized the relationship between PPIA and the scores of the immune microenvironment, which included the stromal score, immune score, and estimate score, for different cancers. The findings indicated a negative correlation between PPIA expression levels and the stromal, immune, and estimate scores in multiple cancers. Figure 11B-D illustrated that the tumor immune microenvironment scores for LUAD exhibited a negative correlation with the PPIA expression level. Relationship between PPIA expression and immune microenvironment scores and immune checkpoint genes. (A) The relationship between PPIA and the scores of the immune microenvironment scores for different cancers. (B) The relationship between PPIA and stromal score in LUAD. (C) The relationship between PPIA and immune score in LUAD. (D) The relationship between PPIA and estimate score in LUAD. (E) Correlation of PPIA expression with immune checkpoint genes. (F) Correlations between PPIA and several MMR-associated genes. * p < 0.05; ** p < 0.01; *** p < 0.001 PPIA is Significantly Related to Immune Regulators and Related Genes In multiple tumors, PPIA expression was inversely associated with most or subsets of immune checkpoint genes. In LUAD, PPIA negatively correlated with immune-related genes (Figure 11E). PPIA also correlated significantly with MMR-associated genes in most solid tumors (Figure 11F). In certain cancers, PPIA was inversely correlated with MHC genes, chemokines, and chemokine receptors, a pattern consistent in LUAD (Figure 12). Association between PPIA expression and immune related genes. (A) MHC genes by heatmap. (B) chemokines by heatmap. (C) chemokine receptors by heatmap. (D) MHC genes by radar chart. (E) Chemokines by radar chart. (F) Chemokine receptors by radar chart. * p < 0.05; ** p < 0.01; *** p < 0.001 PPIA Serves as a Predictive Biomarker for Drug Therapy Efficacy in LUAD PPIA expression correlated significantly with sensitivity to multiple drugs, suggesting potential as a drug sensitivity indicator (Supplementary Figure S2). In some immunotherapy cohorts, PPIA expression differed significantly between response (R) and non-response (NR) groups (p = 0.0097), with ROC curves showing good predictive accuracy for some immunotherapies (AUC > 0.7, e.g., 0.782, 0.716). Kaplan-Meier curves showed significant survival differences between high and low PPIA groups in the Lauss 2017 cohort (CAR-T treatment, p = 0.046), with low-expression patients having better prognosis; while other cohorts showed no significant difference, high PPIA expression was associated with shorter survival (Supplementary Figure S3). Further validation with large LUAD cohorts is needed. PPIA Expression is Associated With DNA Damage Repair-Related Genes To provide preliminary mechanistic insight into the relationship between PPIA and DNA damage repair, we further examined the transcriptional correlation between PPIA and representative DNA damage repair-related genes. PPIA expression showed significant correlations with several genes involved in DNA damage checkpoint activation and repair pathways, such as ATM, BRCA1, BRCA2, RAD51, CHEK1, CHEK2, PARP1, XRCC5, and XRCC6. These findings suggest that PPIA may be associated with a DNA repair-related transcriptional program in LUAD (Supplementary Figure S4). PPIA is involved in the DNA Damage Repair Pathway Since radiotherapy kills LUAD cells by mediating DNA damage, and GO analysis linked PPIA to DNA repair processes, we first excluded potential confounding effects on cell proliferation. CCK-8 assays confirmed that neither knockdown nor overexpression of PPIA significantly altered the proliferation of A549 and H1299 cells (Supplementary Figure S5), supporting a role of PPIA in DNA damage repair rather than cell proliferation. Subsequently, PPIA knockdown significantly enhanced the radiosensitivity of LUAD cells and increased the number of γ-H2AX foci (a key DNA damage indicator) (Figure 13A-G). Conversely, PPIA overexpression yielded opposite results, reducing radiosensitivity and decreasing γ-H2AX foci (Figure 13H-N). The full gel image is presented in Supplementary Figure S6. Tumor-promoting properties of PPIA by cellular experiments. (A) Knocked down PPIA in A549 and H1299 cells. (B) The sensitivity of LUAD to radiotherapy in A549 cells. (C) The sensitivity of LUAD to radiotherapy in H1299 cells. (D-G) The effect of PPIA suppression on the abundance of γ-H2AX foci in A549 and H1299 cells. (H) Overexpression PPIA in A549 and H1299 cells. (I-J) The sensitivity of LUAD to radiotherapy in A549 cells and H1299 cells. (K-N) The effect of PPIA overexpression on the abundance of γ-H2AX foci in A549 and H1299 cells. * p < 0.05; ** p < 0.01; *** p < 0.001 Discussion PPIA, also known as CypA, belongs to the cyclophilin family and possesses PPIase activity. The PPIA gene is located at the 7p13 locus on chromosome 7. Structurally, CypA consists of an eight-stranded antiparallel β-barrel flanked by α-helices. 15 Its PPIase function involves the modulation of protein folding, transport, and functions.16,17 PPIases typically assist in protein folding by catalyzing the conformational cis/trans isomerization of prolyl bonds. 18 Several investigations have implicated PPIA in the initiation, advancement, and therapeutic response of lung cancer. The deletion of PPIA facilitates the degradation of the NRF2 protein and represses NRF2-mediated proliferation in NSCLC cells. Cyclosporin A (CsA) interferes with NRF2/KLF5/SLC1A5 pathway-regulated glutamine metabolism, thereby inhibiting the growth of NRF2-overactive NSCLC cells. 19 Research suggests that PPIA is upregulated in NSCLC, and patients exhibiting high levels of PPIA expression have a notably reduced progression-free survival compared to those with low expression levels. The extent of PPIA expression significantly correlates with the protein levels of HIF-1α, and hypoxic conditions induce an increase in PPIA expression in NSCLC. 20 Ma et al.’s study showed that PPIA shields A549 cells from H2O2-induced oxidative harm and apoptosis by activating the PI3K/Akt/mTOR pathway. 21 These findings support an oncogenic role of PPIA in lung cancer and provide a rationale for further investigating its functional relevance in LUAD. A major finding of the present study is that PPIA is involved in DNA damage repair and radiosensitivity in LUAD cells. In addition to GO enrichment results linking PPIA-associated proteins to DNA metabolism, DNA repair complexes, replication forks, and cell cycle/DNA damage checkpoints, our additional correlation analysis showed that PPIA expression was associated with several DNA damage repair-related genes. Consistently, our experimental validation showed that PPIA knockdown enhanced radiosensitivity and increased γ-H2AX foci formation, whereas PPIA overexpression reduced radiation-induced DNA damage. Importantly, CCK-8 assays showed that PPIA knockdown or overexpression did not significantly affect the proliferation of A549 and H1299 cells, suggesting that the observed radiosensitivity changes were more closely related to DNA damage repair rather than general growth inhibition. These findings indicate that PPIA may contribute to radioresistance by facilitating DNA damage repair in LUAD cells. Beyond DNA damage repair, our multi-omics analyses suggest that PPIA may participate in broader molecular regulation in LUAD. PPIA expression was associated with copy number variations, DNA methylation, DNA methyltransferase activity, and RNA modification-related genes. GSEA further showed enrichment of cancer-related pathways, including E2F targets, MYC targets, G2/M checkpoint, mTORC1 signaling, interferon responses, epithelial-mesenchymal transition, KRAS signaling, and the p53 pathway. These results indicate that PPIA may be involved in multiple oncogenic processes that contribute to LUAD progression and treatment response. In addition to its association with DNA damage repair, PPIA was also linked to the tumor immune microenvironment. Our analyses showed that PPIA expression was negatively correlated with immune infiltration scores and with the infiltration of several immune cell populations, including B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and dendritic cells. PPIA expression was also inversely associated with immune checkpoint genes, MHC genes, chemokines, and chemokine receptors in LUAD. These findings suggest that high PPIA expression may contribute to an immunosuppressive microenvironment. Mechanistically, we hypothesize that PPIA may impair T-cell infiltration by modulating chemokine-mediated immune cell recruitment and/or by activating the CypA/CD147 signaling axis. This hypothesis could be tested in future studies by assessing whether PPIA knockdown restores T-cell–recruiting chemokine expression and enhances T-cell chemotaxis, and whether CD147 blockade reverses the immune-suppressive effects associated with high PPIA expression. Previous studies have reported that pharmacological inhibition of CypA can modulate tumor metastasis and anti-tumor immunity, partly through the CypA/Crk II axis. 5 Recombinant human CypA has also been shown to alter immune cell infiltration within the tumor microenvironment. 22 However, the precise mechanisms by which PPIA regulates immune remodeling in LUAD remain to be clarified. The potential clinical relevance of PPIA is further supported by its prognostic and therapeutic predictive value. In this study, high PPIA expression was associated with unfavorable survival outcomes in LUAD, and multivariate analysis identified PPIA as an independent prognostic factor. Drug sensitivity and immunotherapy response analyses further suggested that PPIA may help predict treatment efficacy. Together with the experimental evidence linking PPIA to radiosensitivity, these findings support the potential of PPIA as both a prognostic biomarker and a therapeutic target in LUAD. This study has several limitations. First, although our bioinformatics analyses integrated multiple public datasets, retrospective database-based analyses may be affected by cohort heterogeneity and require validation in independent prospective cohorts. Second, the functional experiments were performed in vitro using A549 and H1299 lung cancer cell lines, which may not fully recapitulate the complexity of tumor response in vivo. Third, in vivo models were not included to validate the role of PPIA in radiosensitivity in a more physiological context. Finally, the detailed molecular mechanisms by which PPIA regulates DNA damage repair and immune microenvironment remodeling remain to be further investigated. Conclusions In conclusion, our integrated multi-omics investigation establishes PPIA as a multifunctional oncoprotein in LUAD with roles in DNA damage repair, immune microenvironment modulation, and epigenetic regulation. The consistent prognostic value of PPIA across multiple clinical endpoints, combined with its functional impact on treatment response, positions it as both a promising biomarker and a potential therapeutic target. Future studies should focus on developing PPIA-targeted therapies and validating its clinical utility in prospective trials. Supplemental Material Supplemental material - Peptidylprolyl Isomerase a Regulates DNA Damage Repair and Serves as a Prognostic Biomarker in Lung Adenocarcinoma Supplemental material for Peptidylprolyl Isomerase a Regulates DNA Damage Repair and Serves as a Prognostic Biomarker in Lung Adenocarcinoma by Li Zou, Bixin Ren, Ying Wan, Xin Wang, Ruichi Shen, Wenlang Zhu, Limin Jin, Qiliang Peng, Ye Tian in Dose-Response Authors’ Contributions: LZ, BR, YW, and XW performed the computational analysis, and wrote the manuscript. WZ, and RS took part in the data analysis. LJ, QP and YT conceived of the study. All authors read and approved the final manuscript. Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Suzhou Radiotherapy Clinical Medical Center (Szlcyxzx202103), Suzhou Science and Technology Key Research Program (SYWD2025209), Suzhou Applied Basic Research (Medical and Health) Science and Technology Innovation Project (SYWD2024114), and Scientific Research Pre-Study Fund of the Second Affiliated Hospital of Soochow University (SDFEYJC2328), Gusu Health Talent Research Program (GSWS2023043). The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Supplemental Material: Supplemental material for this article is available online. ORCID iDs Li Zou https://orcid.org/0009-0003-3058-3550 Qiliang Peng https://orcid.org/0000-0002-0248-8826 Ethical Considerations All patient-related data used in this study were retrieved from publicly available databases with prior ethical approval and informed consent obtained by the original studies. This study did not involve the collection of new human specimens or any animal experiments; therefore, additional ethical approval and consent to participate were not required. Data Availability Statement All data collected and analyzed in the present study are available from the corresponding author for reasonable request.* References Associated Data Supplementary Materials Supplemental material - Peptidylprolyl Isomerase a Regulates DNA Damage Repair and Serves as a Prognostic Biomarker in Lung Adenocarcinoma Supplemental material for Peptidylprolyl Isomerase a Regulates DNA Damage Repair and Serves as a Prognostic Biomarker in Lung Adenocarcinoma by Li Zou, Bixin Ren, Ying Wan, Xin Wang, Ruichi Shen, Wenlang Zhu, Limin Jin, Qiliang Peng, Ye Tian in Dose-Response Data Availability Statement All data collected and analyzed in the present study are available from the corresponding author for reasonable request.*